Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | GPR183 | P32249 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946777 | 0.90 | HTR2A (0.64) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL20765857 | 0.89 | HTR2A (0.61) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL20765912 | 0.89 | HTR2A (0.61) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL20794838 | 0.89 | HTR2A (0.61) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| Hydrochloric Acid SCHEMBL20765885 | 0.88 | HTR2A (0.61) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| Hydrochloric Acid SCHEMBL20765901 | 0.88 | HTR2A (0.61) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL25570798 | 0.88 | HTR2A (0.71) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL21398189 | 0.87 | HTR2A (0.80) | HTR2AABCB11CYP1A2ADRB2CHRM2 | |
| SCHEMBL3947609 | 0.87 | HTR2A (0.56) | HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL339704 | 0.86 | TACR1 (0.55) | HTR2ASLC6A2OPRM1SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101619057-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC | 2010-01-06 | — | — | CN | claimed |
| CN-1675201-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC (US) | 2005-09-28 | — | — | CN | claimed |
| WO-2019040106-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| CN-101619057-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC | 2010-01-06 | — | — | CN | disclosed |
| CN-100509804-C | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC (US) | 2009-07-08 | — | — | CN | disclosed |
| US-7476682-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7253186-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2007-08-07 | — | — | US | disclosed |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| CN-1675201-A | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARM INC (US) | 2005-09-28 | — | — | CN | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | HTR2A 1/4885ABCB11 1962/4885CYP1A2 144/4885 |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | HTR2A 1/4885ABCB11 1796/4885CYP1A2 140/4885 |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 12/4885ABCB11 726/4885CYP1A2 433/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | HTR2A 3/4885ABCB11 3954/4885CYP1A2 1868/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | HTR2A 1/4885ABCB11 2034/4885CYP1A2 134/4885 |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 10/4885ABCB11 922/4885CYP1A2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.